Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 550

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Exploring vitamin D metabolism and function in cancer

Open access
Jeon, Sang-Min, Shin, Eun-Ae·2018·Experimental & Molecular Medicine
DOI 10.1038/s12276-018-0038-9
Open this paper in CoChat — free account

Abstract

Vitamin D, traditionally known as an essential nutrient, is a precursor of a potent steroid hormone that regulates a broad spectrum of physiological processes. In addition to its classical roles in bone metabolism, epidemiological, preclinical, and cellular research during the last decades, it revealed that vitamin D may play a key role in the prevention and treatment of many extra-skeletal diseases such as cancer. Vitamin D, as a prohormone, undergoes two-step metabolism in liver and kidney to produce a biologically active metabolite, calcitriol, which binds to the vitamin D receptor (VDR) for the regulation of expression of diverse genes. In addition, recent studies have revealed that vitamin D can also be metabolized and activated through a CYP11A1-driven non-canonical metabolic pathway. Numerous anticancer properties of vitamin D have been proposed, with diverse effects on cancer development and progression. However, accumulating data suggest that the metabolism and functions of vitamin D are dysregulated in many types of cancer, conferring resistance to the antitumorigenic effects of vitamin D and thereby contributing to the development and progression of cancer. Thus, understanding dysregulated vitamin D metabolism and function in cancer will be critical for the development of promising new strategies for successful vitamin D-based cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s12276-018-0038-9

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 164

  1. Zhang, R. & Naughton, D. P. Vitamin D in health and disease: current perspectives. Nutr. J. 9, 65 (2010). · DOI · Paper page
  2. Bouillon, R. et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29, 726–776 (2008). · DOI · Paper page
  3. Bikle, D. D. Extraskeletal actions of vitamin D. Ann. N. Y Acad. Sci. 1376, 29–52 (2016). · DOI
  4. Holick, M. F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 80, 1678S–1688S (2004). · DOI · Paper page
  5. Wang, H. et al. Vitamin D and chronic diseases. Aging Dis. 8, 346–353 (2017). · DOI · Paper page
  6. Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E. & Feldman, B. J. The role of vitamin D in reducing cancer risk and progression. Nat. Rev. Cancer 14, 342–357 (2014). · DOI · Paper page
  7. Bertino, J. R. Landmark study: the relation of solar radiation to cancer mortality in North America. Cancer Res 76, 185 (2016). · DOI
  8. Apperly, F. L. The relation of solar radiation to cancer mortality in North America. Cancer Res 1, 191 (1941).
  9. Garland, C. F. & Garland, F. C. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J. Epidemiol. 9, 227–231 (1980). · DOI · Paper page
  10. Hanchette, C. L. & Schwartz, G. G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70, 2861–2869 (1992). · DOI
  11. Grant, W. B. & Mohr, S. B. Ecological studies of ultraviolet B, vitamin D and cancer since 2000. Ann. Epidemiol. 19, 446–454 (2009). · DOI
  12. Garland, C. F. et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 2, 1176–1178 (1989). · DOI · Paper page
  13. Engel, P. et al. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol. Biomark. Prev. 19, 2341–2350 (2010). · DOI
  14. Tretli, S., Hernes, E., Berg, J. P., Hestvik, U. E. & Robsahm, T. E. Association between serum 25(OH)D and death from prostate cancer. Br. J. Cancer 100, 450–454 (2009). · DOI
  15. Ahonen, M. H., Tenkanen, L., Teppo, L., Hakama, M. & Tuohimaa, P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11, 847–852 (2000). · DOI · Paper page
  16. Giovannucci, E. et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl. Cancer Inst. 98, 451–459 (2006). · DOI · Paper page
  17. Giammanco, M. et al. Vitamin D in cancer chemoprevention. Pharm. Biol. 53, 1399–1434 (2015). · DOI
  18. Fleet, J. C., DeSmet, M., Johnson, R. & Li, Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J. 441, 61–76 (2012). · DOI · Paper page
  19. Ma, Y., Trump, D. L. & Johnson, C. S. Vitamin D in combination cancer treatment. J. Cancer 1, 101–107 (2010). · DOI
  20. Mehta, R. G., Peng, X., Alimirah, F., Murillo, G. & Mehta, R. Vitamin D and breast cancer: emerging concepts. Cancer Lett. 334, 95–100 (2013). · DOI
  21. Heaney, R. P. Vitamin D in health and disease. Clin. J. Am. Soc. Nephrol. 3, 1535–1541 (2008). · DOI · Paper page
  22. Japelt, R. B. & Jakobsen, J. Vitamin D in plants: a review of occurrence, analysis, and biosynthesis. Front Plant Sci. 4, 136 (2013). · DOI · Paper page
  23. Jones, G., Prosser, D. E. & Kaufmann, M. Cytochrome P450-mediated metabolism of vitamin D. J. Lipid Res 55, 13–31 (2014). · DOI · Paper page
  24. Schuster, I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys. Acta 1814, 186–199 (2011). · DOI · Paper page
  25. St-Arnaud, R. et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141, 2658–2666 (2000). · DOI · Paper page
  26. Masuda, S. et al. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 146, 825–834 (2005). · DOI
  27. Haussler, M. R., Jurutka, P. W., Mizwicki, M. & Norman, A. W. Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms. Best. Pract. Res Clin. Endocrinol. Metab. 25, 543–559 (2011). · DOI · Paper page
  28. Pike, J. W. & Meyer, M. B. Fundamentals of vitamin D hormone-regulated gene expression. J. Steroid Biochem Mol. Biol. 144(Pt A), 5–11 (2014). · DOI
  29. Duran, A. et al. p62/SQSTM1 by binding to vitamin D receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer. Cancer Cell 30, 595–609 (2016). · DOI
  30. Nemere, I., Safford, S. E., Rohe, B., DeSouza, M. M. & Farach-Carson, M. C. Identification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS) binding protein. J. Steroid Biochem. Mol. Biol. 89-90, 281–285 (2004). · DOI
  31. Slominski, A. T. et al. Endogenously produced nonclassical vitamin D hydroxy-metabolites act as “biased” agonists on VDR and inverse agonists on RORalpha and RORgamma. J. Steroid Biochem. Mol. Biol. 173, 42–56 (2017). · DOI · Paper page
  32. Slominski, A. et al. The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. FEBS J. 272, 4080–4090 (2005). · DOI · Paper page
  33. Guryev, O., Carvalho, R. A., Usanov, S., Gilep, A. & Estabrook, R. W. A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc. Natl. Acad. Sci. USA 100, 14754–14759 (2003). · DOI · Paper page
  34. Slominski, A. T. et al. The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. J. Steroid Biochem. Mol. Biol. 144(Pt A), 28–39 (2014). · DOI · Paper page
  35. Slominski, A. T. et al On the role of classical and novel forms of vitamin D in melanoma progression and management. J. Steroid Biochem. Mol. Biol. https://doi.org/10.1016/j.jsbmb.2017.06.013 (2017). · DOI
  36. Slominski, A. T. et al. RORalpha and ROR gamma are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J. 28, 2775–2789 (2014). · DOI · Paper page
  37. Cook, D. N., Kang, H. S. & Jetten, A. M. Retinoic acid-related orphan receptors (RORs): regulatory functions in immunity, development, circadian rhythm, and metabolism. Nucl. Recept. Res 2, 101185 (2015). · DOI
  38. Jones, G., Prosser, D. E. & Kaufmann, M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch. Biochem Biophys. 523, 9–18 (2012). · DOI · Paper page
  39. Zierold, C., Darwish, H. M. & DeLuca, H. F. Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter. J. Biol. Chem. 270, 1675–1678 (1995). · DOI
  40. Meyer, M. B., Goetsch, P. D. & Pike, J. W. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J. Biol. Chem. 285, 15599–15610 (2010). · DOI
  41. Kim, M. S., Fujiki, R., Kitagawa, H. & Kato, S. 1Alpha,25(OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene. Mol. Cell Endocrinol. 265-266, 168–173 (2007). · DOI
  42. Martin, A., David, V. & Quarles, L. D. Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 92, 131–155 (2012). · DOI · Paper page
  43. Khundmiri, S. J., Murray, R. D. & Lederer, E. PTH and vitamin D. Compr. Physiol. 6, 561–601 (2016). · DOI · Paper page
  44. Zierold, C., Nehring, J. A. & DeLuca, H. F. Nuclear receptor 4A2 and C/EBPbeta regulate the parathyroid hormone-mediated transcriptional regulation of the 25-hydroxyvitamin D3-1alpha-hydroxylase. Arch. Biochem Biophys. 460, 233–239 (2007). · DOI
  45. Rost, C. R., Bikle, D. D. & Kaplan, R. A. In vitro stimulation of 25-hydroxycholecalciferol 1 alpha-hydroxylation by parathyroid hormone in chick kidney slices: evidence for a role for adenosine 3’,5’-monophosphate. Endocrinology 108, 1002–1006 (1981). · DOI
  46. Zierold, C., Reinholz, G. G., Mings, J. A., Prahl, J. M. & DeLuca, H. F. Regulation of the procine 1,25-dihydroxyvitamin D3-24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D3 and parathyroid hormone in AOK-B50 cells. Arch. Biochem. Biophys. 381, 323–327 (2000). · DOI
  47. Zierold, C., Mings, J. A. & DeLuca, H. F. Parathyroid hormone regulates 25-hydroxyvitamin D(3)-24-hydroxylase mRNA by altering its stability. Proc. Natl. Acad. Sci. USA 98, 13572–13576 (2001). · DOI
  48. Riccardi, D. & Brown, E. M. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am. J. Physiol. Ren. Physiol. 298, F485–F499 (2010). · DOI · Paper page
  49. Perwad, F. et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146, 5358–5364 (2005). · DOI · Paper page
  50. Perwad, F., Zhang, M. Y., Tenenhouse, H. S. & Portale, A. A. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am. J. Physiol. Ren. Physiol. 293, F1577–F1583 (2007). · DOI · Paper page
  51. Shimada, T. et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Ren. Physiol. 289, F1088–F1095 (2005). · DOI · Paper page
  52. Krishnan, A. V. & Feldman, D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr. Relat. Cancer 17, R19–R38 (2010). · DOI
  53. Moreno, J. et al. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65, 7917–7925 (2005). · DOI
  54. Yuan, L., Jiang, R., Yang, Y., Ding, S. & Deng, H. 1,25-Dihydroxyvitamin D3 inhibits growth of the breast cancer cell line MCF-7 and downregulates cytochrome P4501B1 through the COX-2/PGE2 pathway. Oncol. Rep. 28, 2131–2137 (2012). · DOI
  55. Thill, M. et al. Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cells. Anticancer Res. 32, 367–372 (2012).
  56. Cordes, T. et al. Correlation of prostaglandin metabolizing enzymes and serum PGE2 levels with vitamin D receptor and serum 25(OH)2D3 levels in breast and ovarian cancer. Anticancer Res. 32, 351–357 (2012).
  57. Nonn, L., Peng, L., Feldman, D. & Peehl, D. M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 66, 4516–4524 (2006). · DOI
  58. Zhang, Y. et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J. Immunol. 188, 2127–2135 (2012). · DOI · Paper page
  59. Wang, Q. et al. Vitamin D inhibits COX-2 expression and inflammatory response by targeting thioesterase superfamily member 4. J. Biol. Chem. 289, 11681–11694 (2014). · DOI
  60. Chen, Y. et al. Vitamin D receptor inhibits nuclear factor kappaB activation by interacting with IkappaB kinase beta protein. J. Biol. Chem. 288, 19450–19458 (2013). · DOI · Paper page
  61. Sun, J. et al. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am. J. Physiol. Endocrinol. Metab. 291, E315–E322 (2006). · DOI
  62. Bessler, H. & Djaldetti, M. 1alpha,25-Dihydroxyvitamin D3 modulates the interaction between immune and colon cancer cells. Biomed. Pharmacother. 66, 428–432 (2012). · DOI
  63. Uberti, F., Morsanuto, V. & Molinari, C. Vitamin D in oxidative stress and diseases (ed Gowder S) A critical evaluation of vitamin D - basic overview. Ch. 02 (InTech, Rijeka, Croatia, 2017). https://doi.org/10.1016/j.jsbmb.2017.06.013. · DOI
  64. Nair-Shalliker, V., Armstrong, B. K. & Fenech, M. Does vitamin D protect against DNA damage? Mutat. Res 733, 50–57 (2012). · DOI · Paper page
  65. Kallay, E. et al. Vitamin D receptor activity and prevention of colonic hyperproliferation and oxidative stress. Food Chem. Toxicol. 40, 1191–1196 (2002). · DOI
  66. Banakar, M. C. et al. 1alpha, 25-dihydroxyvitamin D3 prevents DNA damage and restores antioxidant enzymes in rat hepatocarcinogenesis induced by diethylnitrosamine and promoted by phenobarbital. World J. Gastroenterol. 10, 1268–1275 (2004). · DOI
  67. Peehl, D. M. et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J. Steroid Biochem. Mol. Biol. 92, 131–141 (2004). · DOI
  68. Lambert, J. R. et al. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J. Cell. Physiol. 208, 566–574 (2006). · DOI
  69. Swami, S., Raghavachari, N., Muller, U. R., Bao, Y. P. & Feldman, D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. 80, 49–62 (2003). · DOI
  70. Bao, B. Y., Ting, H. J., Hsu, J. W. & Lee, Y. F. Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J. Cancer 122, 2699–2706 (2008). · DOI
  71. Zhang, X. et al. Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J. Biol. Chem. 280, 35458–35468 (2005). · DOI
  72. Manna, P. & Jain, S. Vitamin D (VD) prevents oxidative stress via regulating NOX4/Nrf2/Trx signaling cascade and upregulates SIRT1-mediated AMPK/IRS1/GLUT4 pathway and glucose uptake in high glucose treated 3T3L1 adipocytes. FASEB J. 29(1 Supplement), 253 (2015). 1.
  73. Nakai, K. et al. Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats. Am. J. Hypertens. 27, 586–595 (2014). · DOI
  74. Berridge, M. J. Vitamin D cell signalling in health and disease. Biochem Biophys. Res. Commun. 460, 53–71 (2015). · DOI
  75. Ting, H. J. et al. A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res. 72, 958–968 (2012). · DOI
  76. Jiang, F., Li, P., Fornace, A. J. Jr., Nicosia, S. V. & Bai, W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J. Biol. Chem. 278, 48030–48040 (2003). · DOI
  77. Akhter, J., Chen, X., Bowrey, P., Bolton, E. J. & Morris, D. L. Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis. Colon Rectum 40, 317–321 (1997). · DOI
  78. Gonzalo, S. Novel roles of 1alpha,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment. J. Steroid Biochem. Mol. Biol. 144(Pt A), 59–64 (2014). · DOI
  79. Samuel, S. & Sitrin, M. D. Vitamin D’s role in cell proliferation and differentiation. Nutr. Rev. 66, S116–S124 (2008). · DOI · Paper page
  80. Larriba, M. et al. Vitamin D is a multilevel repressor of Wnt/b-catenin signaling in cancer cells. Cancers 5, 1242 (2013). · DOI
  81. Pendás-Franco, N. et al. DICKKOPF-4 is induced by TCF/β-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1α,25-dihydroxyvitamin D3. Oncogene 27, 4467 (2008). · DOI
  82. An, B. S. et al. Stimulation of Sirt1-regulated FoxO protein function by the ligand-bound vitamin D receptor. Mol. Cell Biol. 30, 4890–4900 (2010). · DOI
  83. Kasiappan, R. et al. 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. J. Biol. Chem. 287, 41297–41309 (2012). · DOI
  84. Chen, A., Davis, B. H., Sitrin, M. D., Brasitus, T. A. & Bissonnette, M. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3). Am. J. Physiol. Gastrointest. Liver Physiol. 283, G864–G874 (2002). · DOI
  85. Yang, L., Yang, J., Venkateswarlu, S., Ko, T. & Brattain, M. G. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J. Cell Physiol. 188, 383–393 (2001). · DOI
  86. Díaz, G. D., Paraskeva, C., Thomas, M. G., Binderup, L. & Hague, A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 60, 2304–2312 (2000).
  87. Pálmer, H. G. et al. Genetic signatures of differentiation induced by 1α,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 63, 7799–7806 (2003).
  88. Pan, L. et al. Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A /sodium butyrate-induced and 5-aza-2′-deoxycytidine-induced PTEN upregulation. FEBS J. 277, 989–999 (2010). · DOI
  89. Sergeev, I. N. Vitamin D and cellular Ca2 + signaling in breast cancer. Anticancer Res. 32, 299–302 (2012).
  90. Wilson, E. N. et al. A switch between cytoprotective and cytotoxic autophagy in the radiosensitization of breast tumor cells by chloroquine and vitamin D. Horm. Cancer 2, 272–285 (2011). · DOI
  91. Sharma, K. et al. A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. Autophagy 10, 2346–2361 (2014). · DOI
  92. Hoyer-Hansen, M., Bastholm, L., Mathiasen, I. S., Elling, F. & Jaattela, M. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ. 12, 1297–1309 (2005). · DOI
  93. Tavera-Mendoza, L. et al. Convergence of vitamin D and retinoic acid signalling at a common hormone response element. EMBO Rep. 7, 180–185 (2006). · DOI
  94. Lisse, T. S. et al. Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J. 25, 937–947 (2011). · DOI
  95. Lisse, T. S. & Hewison, M. Vitamin D: a new player in the world of mTOR signaling. Cell Cycle 10, 1888–1889 (2011). · DOI
  96. Bikle, D. D. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr. Rev. 13, 765–784 (1992).
  97. Bikle, D. D. Extra renal synthesis of 1,25-dihydroxyvitamin D and its health implications. Clin. Rev. Bone Miner. Metab. 7, 114–125 (2009). · DOI
  98. Al-Azhri, J. et al. Tumor expression of vitamin D receptor and breast cancer histopathological characteristics and prognosis. Clin. Cancer Res. 23, 97–103 (2017). · DOI
  99. Zhang, Y. et al. VDR status arbitrates the prometastatic effects of tumor-associated macrophages. Mol. Cancer Res 12, 1181–1191 (2014). · DOI
  100. Lopes, N. et al. Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10, 483 (2010). · DOI
  101. Thill, M. et al. Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J. Steroid Biochem. Mol. Biol. 121, 387–390 (2010). · DOI
  102. Hendrickson, W. K. et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J. Clin. Oncol. 29, 2378–2385 (2011). · DOI
  103. Srinivasan, M., Parwani, A. V., Hershberger, P. A., Lenzner, D. E. & Weissfeld, J. L. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J. Steroid Biochem. Mol. Biol. 123, 30–36 (2011). · DOI
  104. Jozwicki, W., Brozyna, A. A., Siekiera, J. & Slominski, A. T. Expression of vitamin D receptor (VDR) positively correlates with survival of urothelial bladder cancer patients. Int J. Mol. Sci. 16, 24369–24386 (2015). · DOI
  105. Palmer, H. G. et al. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat. Med. 10, 917–919 (2004). · DOI · Paper page
  106. Pena, C. et al. E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. Hum. Mol. Genet. 14, 3361–3370 (2005). · DOI
  107. Mittal, M. K., Myers, J. N., Misra, S., Bailey, C. K. & Chaudhuri, G. In vivo binding to and functional repression of the VDR gene promoter by SLUG in human breast cells. Biochem. Biophys. Res. Commun. 372, 30–34 (2008). · DOI
  108. Maruyama, R. et al. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res. 66, 4574–4583 (2006). · DOI
  109. Stambolsky, P. et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 17, 273–p285 (2010). · DOI · Paper page
  110. DeSmet, M. L. & Fleet, J. C. Constitutively active RAS signaling reduces 1,25 dihydroxyvitamin D-mediated gene transcription in intestinal epithelial cells by reducing vitamin D receptor expression. J. Steroid Biochem. Mol. Biol. 173, 194–201 (2017). · DOI
  111. Zhang, Z. et al. Constitutive activation of the mitogen-activated protein kinase pathway impairs vitamin D signaling in human prostate epithelial cells. J. Cell. Physiol. 224, 433–442 (2010). · DOI
  112. Solomon, C., White, J. H. & Kremer, R. Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. J. Clin. Invest. 103, 1729–1735 (1999). · DOI
  113. Marik, R. et al. DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biol. Ther. 10, 44–53 (2010). · DOI
  114. Liel, Y., Shany, S., Smirnoff, P. & Schwartz, B. Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 140, 280–285 (1999). · DOI
  115. Mohri, T., Nakajima, M., Takagi, S., Komagata, S. & Yokoi, T. MicroRNA regulates human vitamin D receptor. Int. J. Cancer 125, 1328–1333 (2009). · DOI
  116. Essa, S. et al. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J. Steroid Biochem. Mol. Biol. 121, 110–113 (2010). · DOI
  117. Hsu, J. W. et al. Suppression of prostate cancer cell rolling and adhesion to endothelium by 1alpha,25-dihydroxyvitamin D3. Am. J. Pathol. 178, 872–880 (2011). · DOI
  118. Segersten, U. et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J. Clin. Endocrinol. Metab. 87, 2967–2972 (2002).
  119. Matusiak, D. & Benya, R. V. CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J. Histochem. Cytochem. 55, 1257–1264 (2007). · DOI
  120. Chen, T. C., Holick, M. F., Lokeshwar, B. L., Burnstein, K. L. & Schwartz, G. G. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. (eds Reichrath, J., Tilgen, W., Friedrich, M.) Vitamin D analogs in cancer prevention and therapy pp. 273-288 (Springer, Berlin, Heidelberg, Germany, 2003) https://doi.org/10.1007/978-3-642-55580-0_20. · DOI
  121. Mawer, E. B. et al. Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line. J. Clin. Endocrinol. Metab. 79, 554–560 (1994).
  122. Hansdottir, S. et al. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J. Immunol. 181, 7090–7099 (2008). · DOI · Paper page
  123. Clinckspoor, I. et al. Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J. Histochem. Cytochem. 60, 502–511 (2012). · DOI
  124. Lopes, N. et al. 1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Res. 32, 249–257 (2012).
  125. Blomberg Jensen, M. et al. Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J. Steroid Biochem. Mol. Biol. 121, 376–382 (2010). · DOI
  126. Urbschat, A. et al. Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma. Eur. J. Clin. Invest. 43, 1282–1290 (2013). · DOI
  127. Yokomura, K. et al. Increased expression of the 25-hydroxyvitamin D(3)-1alpha-hydroxylase gene in alveolar macrophages of patients with lung cancer. J. Clin. Endocrinol. Metab. 88, 5704–5709 (2003). · DOI
  128. Zehnder, D. et al. Synthesis of 1,25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 13, 621–629 (2002). · DOI · Paper page
  129. Albertson, D. G. et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 25, 144–146 (2000). · DOI · Paper page
  130. Horvath, H. C. et al. The candidate oncogene CYP24A1: a potential biomarker for colorectal tumorigenesis. J. Histochem. Cytochem. 58, 277–285 (2010). · DOI
  131. Cross, H. S., Bises, G., Lechner, D., Manhardt, T. & Kallay, E. The vitamin D endocrine system of the gut–its possible role in colorectal cancer prevention. J. Steroid Biochem. Mol. Biol. 97, 121–128 (2005). · DOI
  132. Brozek, W., Manhardt, T., Kallay, E., Peterlik, M. & Cross, H. S. Relative expression of vitamin D hydroxylases, CYP27B1 and CYP24A1, and of cyclooxygenase-2 and heterogeneity of human colorectal cancer in relation to age, gender, tumor location, and malignancy: results from factor and cluster analysis. Cancers (Basel) 4, 763–776 (2012).
  133. Chen, G. et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin. Cancer Res. 17, 817–826 (2011). · DOI
  134. Tannour-Louet, M. et al. Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. FASEB J. 28, 364–372 (2014). · DOI
  135. Anderson, M. G., Nakane, M., Ruan, X., Kroeger, P. E. & Wu-Wong, J. R. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol. 57, 234–240 (2006). · DOI
  136. Mitschele, T. et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab. Invest. 84, 693–702 (2004). · DOI
  137. Diesing, D. et al. Analysis of 25-hydroxyvitamin D3–1alpha-hydroxylase in normal and malignant breast tissue. J. Clin. Oncol. 23, 806–806 (2005). · DOI
  138. Sun, H. et al. CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer. Hum. Pathol. 50, 101–108 (2016). · DOI
  139. Mimori, K. et al. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann. Oncol. 15, 236–241 (2004). · DOI
  140. Shiratsuchi, H. et al. Oncogenic potential of CYP24A1 in lung adenocarcinoma. J. Thorac. Oncol. 12, 269–280 (2017). · DOI
  141. Osanai, M. & Lee, G. H. CYP24A1-induced vitamin D insufficiency promotes breast cancer growth. Oncol. Rep. 36, 2755–2762 (2016). · DOI
  142. Muindi, J. R. et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 151, 4301–4312 (2010). · DOI
  143. Luo, W. et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res. 70, 5953–5962 (2010). · DOI
  144. Brozyna, A. A. et al. CYP24A1 expression inversely correlates with melanoma progression: clinic-pathological studies. Int J. Mol. Sci. 15, 19000–19017 (2014). · DOI
  145. Hobaus, J. et al. Increased copy-number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer. Int J. Cancer 133, 1380–1388 (2013). · DOI
  146. Meijer, G. A. et al. Progression from colorectal adenoma to carcinoma is associated with non- random chromosomal gains as detected by comparative genomic hybridisation. J. Clin. Pathol. 51, 901–909 (1998). · DOI
  147. Komagata, S. et al. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol. Pharmacol. 76, 702–709 (2009). · DOI
  148. Borkowski, R. et al. Genetic mutation of p53 and suppression of the miR-17 approximately 92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling. Cancer Res. 75, 666–675 (2015). · DOI
  149. Luo, W. et al. Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Res. 73, 2289–2297 (2013). · DOI
  150. Trembley, J. H. et al. Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors 36, 187–195 (2010). · DOI
  151. Ramnath, N. et al. Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma. J. Thorac. Oncol. 9, 473–482 (2014). · DOI
  152. Hobaus, J., Fetahu, I., Khorchide, M., Manhardt, T. & Kallay, E. Epigenetic regulation of the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1) in colon cancer cells. J. Steroid Biochem. Mol. Biol. 136, 296–299 (2013). · DOI
  153. Tieu, E. W. et al. Rat CYP24A1 acts on 20-hydroxyvitamin D(3) producing hydroxylated products with increased biological activity. Biochem. Pharmacol. 84, 1696–1704 (2012). · DOI · Paper page
  154. Brozyna, A. A., Jozwicki, W., Skobowiat, C., Jetten, A. & Slominski, A. T. RORalpha and RORgamma expression inversely correlates with human melanoma progression. Oncotarget 7, 63261–63282 (2016). · DOI
  155. Fan, Z., Wang, Z., Chen, W., Cao, Z. & Li, Y. Association between the CYP11 family and six cancer types. Oncol. Lett. 12, 35–40 (2016). · DOI
  156. Jernberg, E. et al. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS ONE 8, e77407 (2013). · DOI
  157. Fu, R. D., Qiu, C. H., Chen, H. A., Zhang, Z. G. & Lu, M. Q. Retinoic acid receptor-related receptor alpha (RORalpha) is a prognostic marker for hepatocellular carcinoma. Tumour Biol. 35, 7603–7610 (2014). · DOI
  158. Oh, T. G. et al. PRMT2 and RORgamma expression are associated with breast cancer survival outcomes. Mol. Endocrinol. 28, 1166–1185 (2014). · DOI
  159. Lekva, T. et al. Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery. PLoS ONE 8, e66927 (2013). · DOI
  160. Oh, T. G. et al. The nuclear receptor, RORgamma, regulates pathways necessary for breast cancer metastasis. EBioMedicine 6, 59–72 (2016). · DOI
  161. Trump, D. L., Deeb, K. K. & Johnson, C. S. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 16, 1–9 (2010). · DOI
  162. Chen, T. C. & Kittaka, A. Novel vitamin d analogs for prostate cancer therapy. ISRN Urol. 2011, 301490 (2011).
  163. Byers, S. W., Rowlands, T., Beildeck, M. & Bong, Y. S. Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev. Endocr. Metab. Disord. 13, 31–38 (2012). · DOI
  164. Luo, W., Hershberger, P. A., Trump, D. L. & Johnson, C. S. 24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics. J. Steroid Biochem. Mol. Biol. 136, 252–257 (2013). · DOI

Cited by

Metadata

Authors
Jeon, S.-M., & Shin, E.-A.
Venue
Experimental & Molecular Medicine
Publisher
Springer Science and Business Media LLC
Published
2018-04
Volume
50
Issue
4
Pages
1-14
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
DOI
10.1038/s12276-018-0038-9
OpenAlex
W2796593272
Cited by
550
References
13
FWCI
26.52
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.